Baird analyst Jeff Johnson noted Cooper Companies (COO) announced an acquisition of the Paragard IUD from Teva (TEVA) to expand its women's health offering. The analyst likes the acquisition given its minimal integration risk and solid accretion. He remains a buyer of Cooper stock at current levels and would use any pullbacks tied to the announcement as a buying opportunity. Johnson reiterated his Outperform rating and raised his price target to $273 from $267 on Cooper Companies shares.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."